 Ana Gleisner
Concepts (278)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pancreatic Neoplasms | 16 | 2022 | 704 | 3.550 |
Why?
| | Laparoscopy | 8 | 2021 | 395 | 2.960 |
Why?
| | Pancreaticoduodenectomy | 10 | 2021 | 134 | 2.670 |
Why?
| | Adenocarcinoma | 17 | 2022 | 808 | 2.600 |
Why?
| | Sentinel Lymph Node | 7 | 2021 | 38 | 2.490 |
Why?
| | Skin Neoplasms | 11 | 2021 | 755 | 2.440 |
Why?
| | Melanoma | 11 | 2021 | 718 | 2.440 |
Why?
| | Pancreatectomy | 4 | 2021 | 152 | 2.030 |
Why?
| | Lymph Node Excision | 8 | 2021 | 143 | 1.820 |
Why?
| | Minimally Invasive Surgical Procedures | 5 | 2020 | 141 | 1.560 |
Why?
| | Liver Neoplasms | 15 | 2016 | 457 | 1.410 |
Why?
| | Sentinel Lymph Node Biopsy | 9 | 2021 | 126 | 1.370 |
Why?
| | Postoperative Complications | 10 | 2021 | 2181 | 1.330 |
Why?
| | Hepatectomy | 11 | 2021 | 127 | 1.230 |
Why?
| | Esophagectomy | 4 | 2021 | 73 | 1.170 |
Why?
| | Robotic Surgical Procedures | 3 | 2019 | 65 | 1.100 |
Why?
| | Conversion to Open Surgery | 2 | 2020 | 14 | 1.010 |
Why?
| | Nomograms | 2 | 2022 | 52 | 0.980 |
Why?
| | Esophageal Neoplasms | 6 | 2021 | 239 | 0.880 |
Why?
| | Lymph Nodes | 6 | 2020 | 476 | 0.880 |
Why?
| | Retrospective Studies | 39 | 2022 | 11642 | 0.840 |
Why?
| | Survival Rate | 21 | 2021 | 1859 | 0.820 |
Why?
| | Aged | 44 | 2022 | 20218 | 0.720 |
Why?
| | Quality of Life | 2 | 2019 | 2230 | 0.720 |
Why?
| | Head and Neck Neoplasms | 6 | 2019 | 420 | 0.670 |
Why?
| | Rectal Neoplasms | 4 | 2022 | 107 | 0.670 |
Why?
| | Lymphatic Metastasis | 9 | 2020 | 313 | 0.650 |
Why?
| | Colorectal Neoplasms | 7 | 2017 | 589 | 0.650 |
Why?
| | Middle Aged | 51 | 2022 | 28854 | 0.640 |
Why?
| | Colectomy | 3 | 2013 | 81 | 0.590 |
Why?
| | Prognosis | 18 | 2020 | 3546 | 0.590 |
Why?
| | Carcinoma, Pancreatic Ductal | 3 | 2022 | 180 | 0.570 |
Why?
| | Neoplasm Recurrence, Local | 7 | 2019 | 805 | 0.560 |
Why?
| | Liver Transplantation | 9 | 2009 | 751 | 0.560 |
Why?
| | Liver Failure | 3 | 2009 | 86 | 0.560 |
Why?
| | Colonic Neoplasms | 2 | 2013 | 216 | 0.510 |
Why?
| | Neoplasm Staging | 8 | 2022 | 1215 | 0.510 |
Why?
| | Humans | 75 | 2022 | 114571 | 0.500 |
Why?
| | Female | 60 | 2022 | 63070 | 0.500 |
Why?
| | Risk Assessment | 5 | 2019 | 3208 | 0.480 |
Why?
| | Neoadjuvant Therapy | 8 | 2022 | 283 | 0.470 |
Why?
| | Decision Making | 1 | 2019 | 799 | 0.470 |
Why?
| | Male | 56 | 2022 | 60817 | 0.470 |
Why?
| | Breast Neoplasms | 3 | 2020 | 1925 | 0.470 |
Why?
| | Follow-Up Studies | 13 | 2021 | 4950 | 0.450 |
Why?
| | Treatment Outcome | 18 | 2021 | 9190 | 0.430 |
Why?
| | Databases, Factual | 6 | 2019 | 1161 | 0.390 |
Why?
| | Benchmarking | 2 | 2021 | 156 | 0.380 |
Why?
| | Aged, 80 and over | 16 | 2021 | 6818 | 0.380 |
Why?
| | Single Photon Emission Computed Tomography Computed Tomography | 2 | 2019 | 16 | 0.370 |
Why?
| | Peritoneal Neoplasms | 2 | 2020 | 53 | 0.370 |
Why?
| | Propensity Score | 2 | 2019 | 252 | 0.350 |
Why?
| | Mastectomy, Segmental | 2 | 2017 | 89 | 0.330 |
Why?
| | Length of Stay | 4 | 2019 | 1071 | 0.330 |
Why?
| | Catheter Ablation | 2 | 2008 | 325 | 0.300 |
Why?
| | Carcinoma, Hepatocellular | 3 | 2016 | 193 | 0.290 |
Why?
| | Margins of Excision | 3 | 2019 | 31 | 0.290 |
Why?
| | Hyperglycemia | 2 | 2020 | 336 | 0.290 |
Why?
| | Adult | 28 | 2022 | 32077 | 0.280 |
Why?
| | Abdomen, Acute | 1 | 2004 | 19 | 0.270 |
Why?
| | Bacterial Infections | 3 | 2006 | 214 | 0.270 |
Why?
| | Axilla | 2 | 2020 | 61 | 0.250 |
Why?
| | SEER Program | 2 | 2014 | 206 | 0.250 |
Why?
| | Odds Ratio | 4 | 2019 | 1059 | 0.250 |
Why?
| | Lymphoscintigraphy | 2 | 2019 | 13 | 0.250 |
Why?
| | Sunburn | 1 | 2002 | 35 | 0.240 |
Why?
| | Sunscreening Agents | 1 | 2002 | 24 | 0.240 |
Why?
| | Nevus, Pigmented | 1 | 2002 | 39 | 0.240 |
Why?
| | Pelvic Exenteration | 2 | 2019 | 11 | 0.230 |
Why?
| | Survival Analysis | 6 | 2017 | 1410 | 0.230 |
Why?
| | Klatskin Tumor | 1 | 2021 | 4 | 0.230 |
Why?
| | Anesthetics, Inhalation | 1 | 2021 | 19 | 0.220 |
Why?
| | Cytoreduction Surgical Procedures | 2 | 2020 | 43 | 0.220 |
Why?
| | Bile Duct Neoplasms | 1 | 2021 | 54 | 0.220 |
Why?
| | Propofol | 1 | 2021 | 46 | 0.210 |
Why?
| | Prospective Studies | 8 | 2022 | 6288 | 0.210 |
Why?
| | Hyperthermia, Induced | 2 | 2020 | 72 | 0.210 |
Why?
| | Cohort Studies | 8 | 2019 | 5000 | 0.210 |
Why?
| | United States | 12 | 2021 | 12551 | 0.210 |
Why?
| | Disease-Free Survival | 6 | 2022 | 685 | 0.200 |
Why?
| | Anesthesia | 1 | 2021 | 86 | 0.200 |
Why?
| | Scalp | 1 | 2019 | 25 | 0.200 |
Why?
| | Reoperation | 3 | 2017 | 546 | 0.200 |
Why?
| | Combined Modality Therapy | 5 | 2019 | 1217 | 0.190 |
Why?
| | Registries | 2 | 2021 | 1915 | 0.190 |
Why?
| | Pancreatic Diseases | 1 | 2019 | 64 | 0.190 |
Why?
| | Regression Analysis | 2 | 2019 | 1109 | 0.180 |
Why?
| | Skin Pigmentation | 1 | 2019 | 51 | 0.180 |
Why?
| | Appendiceal Neoplasms | 1 | 2017 | 10 | 0.170 |
Why?
| | Patient Reported Outcome Measures | 1 | 2019 | 216 | 0.170 |
Why?
| | Common Bile Duct Neoplasms | 1 | 2017 | 15 | 0.170 |
Why?
| | Ampulla of Vater | 1 | 2017 | 22 | 0.170 |
Why?
| | Population Surveillance | 1 | 2021 | 440 | 0.170 |
Why?
| | Waiting Lists | 2 | 2009 | 195 | 0.170 |
Why?
| | Gastric Outlet Obstruction | 1 | 2017 | 7 | 0.160 |
Why?
| | Pylorus | 1 | 2017 | 11 | 0.160 |
Why?
| | Patient Compliance | 1 | 2021 | 609 | 0.160 |
Why?
| | Carcinoma, Ductal, Breast | 1 | 2017 | 92 | 0.160 |
Why?
| | Genital Neoplasms, Female | 1 | 2017 | 58 | 0.160 |
Why?
| | Nutritional Status | 1 | 2019 | 282 | 0.160 |
Why?
| | Neuroendocrine Tumors | 1 | 2017 | 69 | 0.160 |
Why?
| | Radiotherapy, Intensity-Modulated | 1 | 2018 | 135 | 0.160 |
Why?
| | Cancer Care Facilities | 1 | 2016 | 32 | 0.160 |
Why?
| | Hospitals, High-Volume | 1 | 2016 | 51 | 0.160 |
Why?
| | Hospitals | 1 | 2021 | 502 | 0.160 |
Why?
| | Neuromuscular Agents | 1 | 2017 | 31 | 0.160 |
Why?
| | Disease Management | 1 | 2021 | 605 | 0.160 |
Why?
| | Botulinum Toxins, Type A | 1 | 2017 | 44 | 0.150 |
Why?
| | Chemoradiotherapy | 3 | 2022 | 205 | 0.150 |
Why?
| | Organ Preservation | 3 | 2022 | 87 | 0.150 |
Why?
| | Tomography, Emission-Computed, Single-Photon | 1 | 2016 | 96 | 0.150 |
Why?
| | Adenoma | 1 | 2017 | 185 | 0.150 |
Why?
| | Proportional Hazards Models | 2 | 2022 | 1188 | 0.140 |
Why?
| | Tomography, X-Ray Computed | 2 | 2016 | 2379 | 0.140 |
Why?
| | Time Factors | 4 | 2021 | 7029 | 0.140 |
Why?
| | Anti-Bacterial Agents | 1 | 2004 | 1366 | 0.140 |
Why?
| | Radiosurgery | 1 | 2018 | 299 | 0.140 |
Why?
| | Phenotype | 1 | 2002 | 2842 | 0.130 |
Why?
| | Delivery of Health Care | 1 | 2021 | 734 | 0.130 |
Why?
| | Morbidity | 4 | 2021 | 268 | 0.130 |
Why?
| | Kaplan-Meier Estimate | 2 | 2013 | 899 | 0.130 |
Why?
| | Unnecessary Procedures | 1 | 2014 | 47 | 0.130 |
Why?
| | Antineoplastic Agents | 3 | 2021 | 2035 | 0.130 |
Why?
| | Patient Readmission | 1 | 2019 | 664 | 0.130 |
Why?
| | Trauma Centers | 2 | 2014 | 412 | 0.130 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 2 | 2022 | 1390 | 0.130 |
Why?
| | Risk Factors | 5 | 2019 | 9078 | 0.120 |
Why?
| | Abdomen | 1 | 2013 | 124 | 0.120 |
Why?
| | Metastasectomy | 1 | 2012 | 2 | 0.120 |
Why?
| | Radiation Dosage | 1 | 2014 | 149 | 0.120 |
Why?
| | Clinical Competence | 1 | 2019 | 935 | 0.120 |
Why?
| | Renal Insufficiency | 1 | 2013 | 130 | 0.120 |
Why?
| | Asia | 2 | 2021 | 60 | 0.110 |
Why?
| | Triage | 1 | 2012 | 210 | 0.100 |
Why?
| | Carcinoma, Renal Cell | 1 | 2012 | 175 | 0.100 |
Why?
| | Europe | 2 | 2021 | 332 | 0.100 |
Why?
| | Kidney Transplantation | 2 | 2013 | 520 | 0.100 |
Why?
| | Age Factors | 4 | 2022 | 3280 | 0.100 |
Why?
| | Organ Preservation Solutions | 2 | 2006 | 39 | 0.090 |
Why?
| | Graft Survival | 2 | 2009 | 454 | 0.090 |
Why?
| | Practice Guidelines as Topic | 1 | 2017 | 1541 | 0.090 |
Why?
| | Brain Injuries | 1 | 2014 | 479 | 0.090 |
Why?
| | Practice Patterns, Physicians' | 1 | 2017 | 1241 | 0.090 |
Why?
| | Laparotomy | 1 | 2008 | 113 | 0.090 |
Why?
| | Bile Ducts, Extrahepatic | 1 | 2008 | 25 | 0.090 |
Why?
| | Kidney Neoplasms | 1 | 2012 | 330 | 0.090 |
Why?
| | Biliary Tract Surgical Procedures | 1 | 2008 | 27 | 0.090 |
Why?
| | Gallbladder Neoplasms | 1 | 2007 | 11 | 0.090 |
Why?
| | Neoplasm Invasiveness | 3 | 2020 | 450 | 0.090 |
Why?
| | Neoplasms | 1 | 2021 | 2065 | 0.080 |
Why?
| | Intraoperative Care | 1 | 2007 | 48 | 0.080 |
Why?
| | Cholangitis, Sclerosing | 1 | 2008 | 63 | 0.080 |
Why?
| | Young Adult | 7 | 2022 | 10987 | 0.080 |
Why?
| | Case-Control Studies | 2 | 2007 | 3249 | 0.080 |
Why?
| | Anus Neoplasms | 1 | 2007 | 22 | 0.080 |
Why?
| | Electrocoagulation | 1 | 2007 | 33 | 0.080 |
Why?
| | Chemotherapy, Adjuvant | 3 | 2015 | 327 | 0.080 |
Why?
| | Brazil | 2 | 2008 | 117 | 0.080 |
Why?
| | Congenital Hypothyroidism | 1 | 1986 | 12 | 0.080 |
Why?
| | Fluorouracil | 2 | 2022 | 141 | 0.080 |
Why?
| | Hospital Mortality | 3 | 2019 | 871 | 0.080 |
Why?
| | Ultrasonography, Interventional | 1 | 2007 | 148 | 0.080 |
Why?
| | Mycophenolic Acid | 1 | 2006 | 81 | 0.070 |
Why?
| | Adolescent | 8 | 2022 | 18658 | 0.070 |
Why?
| | Wounds and Injuries | 1 | 2012 | 892 | 0.070 |
Why?
| | Zygomycosis | 1 | 2003 | 6 | 0.070 |
Why?
| | Severity of Illness Index | 2 | 2009 | 2847 | 0.070 |
Why?
| | Radiotherapy, Adjuvant | 2 | 2019 | 194 | 0.070 |
Why?
| | Developmental Disabilities | 1 | 1986 | 250 | 0.060 |
Why?
| | Antibiotic Prophylaxis | 1 | 2004 | 91 | 0.060 |
Why?
| | Hepatocytes | 1 | 2004 | 205 | 0.060 |
Why?
| | Comorbidity | 2 | 2022 | 1645 | 0.060 |
Why?
| | Appendicitis | 1 | 2004 | 116 | 0.060 |
Why?
| | Capecitabine | 1 | 2022 | 45 | 0.060 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2007 | 555 | 0.060 |
Why?
| | CA-19-9 Antigen | 1 | 2022 | 14 | 0.060 |
Why?
| | Anesthesia, Intravenous | 1 | 2021 | 14 | 0.060 |
Why?
| | Surgical Wound Infection | 1 | 2004 | 225 | 0.060 |
Why?
| | Anesthetics, Intravenous | 1 | 2021 | 39 | 0.050 |
Why?
| | Esophagogastric Junction | 1 | 2021 | 42 | 0.050 |
Why?
| | Induction Chemotherapy | 1 | 2021 | 53 | 0.050 |
Why?
| | Tumor Burden | 1 | 2022 | 288 | 0.050 |
Why?
| | Thoracoscopy | 1 | 2020 | 55 | 0.050 |
Why?
| | Liver | 2 | 2006 | 1832 | 0.050 |
Why?
| | Models, Biological | 1 | 2008 | 1807 | 0.050 |
Why?
| | Adenocarcinoma, Mucinous | 1 | 2020 | 51 | 0.050 |
Why?
| | Image-Guided Biopsy | 1 | 2019 | 35 | 0.050 |
Why?
| | Preoperative Period | 1 | 2019 | 109 | 0.050 |
Why?
| | Perioperative Period | 1 | 2017 | 45 | 0.040 |
Why?
| | Parotid Gland | 1 | 2017 | 23 | 0.040 |
Why?
| | Operative Time | 1 | 2017 | 112 | 0.040 |
Why?
| | Occipital Bone | 1 | 2017 | 20 | 0.040 |
Why?
| | Gastric Emptying | 1 | 2017 | 37 | 0.040 |
Why?
| | Carcinoma, Lobular | 1 | 2017 | 59 | 0.040 |
Why?
| | Oxidative Stress | 1 | 2004 | 1231 | 0.040 |
Why?
| | ROC Curve | 2 | 2009 | 489 | 0.040 |
Why?
| | Perioperative Care | 1 | 2018 | 128 | 0.040 |
Why?
| | Health Behavior | 1 | 2002 | 713 | 0.040 |
Why?
| | Obesity | 1 | 2010 | 2643 | 0.040 |
Why?
| | Neck | 1 | 2017 | 87 | 0.040 |
Why?
| | Liver Cirrhosis | 2 | 2008 | 204 | 0.040 |
Why?
| | Raffinose | 2 | 2006 | 20 | 0.040 |
Why?
| | Sex Factors | 1 | 2022 | 1971 | 0.040 |
Why?
| | Preoperative Care | 2 | 2008 | 339 | 0.040 |
Why?
| | Consensus | 1 | 2017 | 458 | 0.040 |
Why?
| | Allopurinol | 2 | 2006 | 86 | 0.040 |
Why?
| | Glucose | 1 | 2020 | 905 | 0.030 |
Why?
| | Quality Indicators, Health Care | 1 | 2017 | 315 | 0.030 |
Why?
| | Lung Neoplasms | 1 | 2007 | 2191 | 0.030 |
Why?
| | Glutathione | 2 | 2006 | 335 | 0.030 |
Why?
| | Adenosine | 2 | 2006 | 217 | 0.030 |
Why?
| | Glasgow Coma Scale | 1 | 2014 | 154 | 0.030 |
Why?
| | Drug Administration Schedule | 1 | 2015 | 808 | 0.030 |
Why?
| | Diagnostic Tests, Routine | 1 | 2014 | 91 | 0.030 |
Why?
| | Vital Signs | 1 | 2012 | 31 | 0.030 |
Why?
| | Guideline Adherence | 1 | 2017 | 541 | 0.030 |
Why?
| | New South Wales | 1 | 2012 | 10 | 0.030 |
Why?
| | Radiation Injuries | 1 | 2014 | 136 | 0.030 |
Why?
| | Incidence | 1 | 2019 | 2454 | 0.030 |
Why?
| | Baltimore | 1 | 2012 | 50 | 0.030 |
Why?
| | Disease Progression | 1 | 2020 | 2486 | 0.030 |
Why?
| | Italy | 1 | 2012 | 94 | 0.030 |
Why?
| | Child | 5 | 2014 | 17859 | 0.030 |
Why?
| | Child, Preschool | 4 | 2014 | 9651 | 0.030 |
Why?
| | Hospital Costs | 1 | 2012 | 126 | 0.030 |
Why?
| | Biological Therapy | 1 | 2011 | 28 | 0.030 |
Why?
| | Pharmaceutical Preparations | 1 | 2013 | 172 | 0.030 |
Why?
| | Chi-Square Distribution | 1 | 2012 | 577 | 0.030 |
Why?
| | Injury Severity Score | 1 | 2012 | 543 | 0.030 |
Why?
| | Glomerular Filtration Rate | 1 | 2013 | 588 | 0.030 |
Why?
| | Infant, Newborn | 2 | 2014 | 5045 | 0.020 |
Why?
| | Multivariate Analysis | 1 | 2013 | 1600 | 0.020 |
Why?
| | Immunosuppressive Agents | 1 | 2013 | 679 | 0.020 |
Why?
| | Carcinoembryonic Antigen | 1 | 2008 | 36 | 0.020 |
Why?
| | Antimetabolites, Antineoplastic | 1 | 2008 | 86 | 0.020 |
Why?
| | Infant | 3 | 2014 | 8096 | 0.020 |
Why?
| | Fluorodeoxyglucose F18 | 1 | 2008 | 129 | 0.020 |
Why?
| | Cholecystectomy | 1 | 2007 | 42 | 0.020 |
Why?
| | Retreatment | 1 | 2007 | 70 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 2012 | 1920 | 0.020 |
Why?
| | Neoplasm, Residual | 1 | 2007 | 91 | 0.020 |
Why?
| | Radiopharmaceuticals | 1 | 2008 | 197 | 0.020 |
Why?
| | Incidental Findings | 1 | 2007 | 82 | 0.020 |
Why?
| | Colorado | 1 | 2017 | 4488 | 0.020 |
Why?
| | Hepatitis B | 1 | 2007 | 44 | 0.020 |
Why?
| | Tablets, Enteric-Coated | 1 | 2006 | 4 | 0.020 |
Why?
| | Positron-Emission Tomography | 1 | 2008 | 303 | 0.020 |
Why?
| | Histidine | 1 | 2006 | 64 | 0.020 |
Why?
| | Biopsy, Needle | 1 | 2007 | 194 | 0.020 |
Why?
| | Psychological Tests | 1 | 1986 | 147 | 0.020 |
Why?
| | Radiography | 1 | 2008 | 850 | 0.020 |
Why?
| | Overweight | 1 | 2010 | 481 | 0.020 |
Why?
| | Tryptophan | 1 | 2006 | 135 | 0.020 |
Why?
| | Graft Rejection | 1 | 2009 | 591 | 0.020 |
Why?
| | Insulin | 2 | 2006 | 2151 | 0.020 |
Why?
| | Glutathione Disulfide | 1 | 2004 | 37 | 0.020 |
Why?
| | Hepatitis C | 1 | 2007 | 218 | 0.020 |
Why?
| | Sulfamethoxypyridazine | 1 | 1983 | 1 | 0.020 |
Why?
| | Trimethoprim | 1 | 1983 | 9 | 0.020 |
Why?
| | Liver Function Tests | 1 | 2004 | 116 | 0.020 |
Why?
| | Anti-Infective Agents, Urinary | 1 | 1983 | 15 | 0.020 |
Why?
| | Gastrointestinal Diseases | 1 | 2006 | 200 | 0.020 |
Why?
| | Amphotericin B | 1 | 2003 | 37 | 0.020 |
Why?
| | Liver Diseases | 1 | 2006 | 274 | 0.020 |
Why?
| | Antifungal Agents | 1 | 2003 | 129 | 0.020 |
Why?
| | Patient Selection | 1 | 2007 | 707 | 0.020 |
Why?
| | Urinary Tract Infections | 1 | 1983 | 126 | 0.010 |
Why?
| | Cause of Death | 1 | 2004 | 390 | 0.010 |
Why?
| | Body Mass Index | 1 | 2010 | 2052 | 0.010 |
Why?
| | Immunocompromised Host | 1 | 2003 | 213 | 0.010 |
Why?
| | Reperfusion Injury | 1 | 2004 | 291 | 0.010 |
Why?
| | Sulfamethoxazole | 1 | 1983 | 6 | 0.000 |
Why?
| | Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 1983 | 39 | 0.000 |
Why?
| | Escherichia coli Infections | 1 | 1983 | 124 | 0.000 |
Why?
| | Drug Combinations | 1 | 1983 | 303 | 0.000 |
Why?
| | Microbial Sensitivity Tests | 1 | 1983 | 296 | 0.000 |
Why?
| | Escherichia coli | 1 | 1983 | 795 | 0.000 |
Why?
| | Clinical Trials as Topic | 1 | 1983 | 1004 | 0.000 |
Why?
|
|
Gleisner's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|